Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

The U.S. FDA on Tuesday granted traditional approval for a first-line combination regimen involving Braftovi, an oral cancer drug developed by Pfizer (PFE) in partnership with companies such as ...

This recent readout follows successful data from another combination including Braftovi in mCRC.

The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on ...

In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population. Non-V600 mutations ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with ...

Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial Fifty-eight patient tumors (56%) harbored ...